Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 515 participants.

Also called NCT07023016

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 515 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07023016
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07023016. Randomized; no masking; primary purpose treatment. Start 2023-11-01 (actual); primary completion 2025-02-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
Acronym
CAESAR
Condition
Acute Decompensated Heart Failure (ADHF)
Intervention (Drug)
Sacubitril / Valsartan
Intervention (Drug)
Ramipril (ACE-inhibitor (ACE inhibitor))
Lead sponsor
National Heart Institute, Egypt (class: other government)
Collaborator
Cairo University (class: other)

Record details

Record id
cardio:ct-nct07023016
Content hash
4ac578c089b0cda9d4370094ea2614926e370f200fc9212ee070154e3f7f3f4e